Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
about
Vaccines for gonorrhea: can we rise to the challenge?Stable dry powder formulation for nasal delivery of anthrax vaccineMucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbitsEvaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)Transferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunityA comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.Innate endogenous adjuvants prime to desirable immune responses via mucosal routesMaximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine productionStructure and function of chicken interleukin-1 beta mutants: uncoupling of receptor binding and in vivo biological activity.Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus ChallengeRetention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.Cytokines: the future of intranasal vaccine adjuvants.Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants.IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid Cells.
P2860
Q21131153-7C3205CB-3350-4B05-9C1D-8530B376C1E2Q28386405-3239B556-DAB9-46D0-8827-3A503268CCFFQ28476839-5CE39E6B-2966-4B99-A672-06BA9BA65547Q30392892-1ED84B57-4C8B-4C5B-8600-E04E37191D85Q30468622-561D9FC2-AC46-4BE9-AA63-A3F646966E04Q33708572-3CBE9269-F031-487B-B495-4AAC8300CD6CQ34564412-C089ABAC-18DB-454C-A318-D8F488A301E0Q35143128-8FD050EF-78F7-4398-80E4-8FC0ED915C90Q35802766-2A87ACF7-EF62-48E2-8928-3782DC4B8B26Q36985965-A37D598D-D35D-44BA-B64B-8CAF0B0F3EB4Q37067250-F9C877D1-515B-489E-8AC1-0FCC232A9237Q37184111-C07B5A71-D2BC-4953-AD6C-C917257EF45AQ37914007-45BAB3D6-2867-4653-A538-845E050A45DAQ38335733-60ACF5BC-0BFB-4962-B657-9E2DCC657751Q38999003-ECDAB74B-A5ED-4895-AEEF-8BFB3E61C981Q48111203-41BC166C-696B-4B7C-8C89-39A9A77174E2
P2860
Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effective induction of protect ...... vaccines adjuvanted with IL-1.
@ast
Effective induction of protect ...... vaccines adjuvanted with IL-1.
@en
type
label
Effective induction of protect ...... vaccines adjuvanted with IL-1.
@ast
Effective induction of protect ...... vaccines adjuvanted with IL-1.
@en
prefLabel
Effective induction of protect ...... vaccines adjuvanted with IL-1.
@ast
Effective induction of protect ...... vaccines adjuvanted with IL-1.
@en
P2093
P2860
P1433
P1476
Effective induction of protect ...... vaccines adjuvanted with IL-1
@en
P2093
Anthony J Hickey
Catherine R Doil
David E Briles
Kathleen A Ashcraft
Leslie S Casey
Neil L Sparks
Richard S Dondero
Shaun M Kirwan
Sheena H Wang
Susan K Hollingshead
P2860
P304
P356
10.1016/J.VACCINE.2010.08.006
P407
P577
2010-08-17T00:00:00Z